Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance
- 1 January 2022
- journal article
- research article
- Published by Elsevier in Experimental Hematology
- Vol. 105, 39-49
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 22 references indexed in Scilit:
- Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML CellsClinical Cancer Research, 2016
- CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cellsJournal of Hematology & Oncology, 2014
- Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199Leukemia, 2014
- Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51PLOS ONE, 2013
- Panobinostat Synergistically Enhances the Cytotoxic Effects of Cisplatin, Doxorubicin or Etoposide on High-Risk Neuroblastoma CellsPLOS ONE, 2013
- Targeting the B-Cell Lymphoma/Leukemia 2 Family in CancerJournal of Clinical Oncology, 2012
- Mechanisms of Synergistic Antileukemic Interactions between Valproic Acid and Cytarabine in Pediatric Acute Myeloid LeukemiaClinical Cancer Research, 2010
- A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic MalignanciesClinical Cancer Research, 2008
- Mcl‐1 and Bcl‐2/Bax ratio are associated with treatment response but not with Rai stage in B‐cell chronic lymphocytic leukemiaAmerican Journal of Hematology, 2003
- High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rateLeukemia, 1997